Literature DB >> 304736

Blood lymphocytes surface markers and clinical findings in chronic lympoproliferative disorders.

U Jayaswal, S Roath, R D Hyde, D M Chisholm, J L Smith.   

Abstract

Surface receptors on peripheral blood lymphocytes have been studied in 43 cases with chronic lymphocytic leukaemia (CLL), and five cases with lymphoma and overspill. One quarter of the cases with CLL had lymphocytes with no detectable surface immunoglobulin (SIg) by direct fluorescent antibody staining. The remainder had SIgM, which was associated with SIgD in one third of the cases. 70% of the SIg negative group had extensive extramedullary involvement (EMI) compared with 35% of the SIg positive group at presentation; correspondingly more of the SIg negative group were treated. 46% of the SIg negative group were CLL patients of more than 3 years standing compared with 9% of the SIgM+D group and 32% of the SIgM group. Some explanations for this pattern are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 304736     DOI: 10.1111/j.1365-2141.1977.tb06836.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Lymphocyte surface marker studies in the diagnosis of unexplained lymphocytosis.

Authors:  M C Quantz; J B Robinson; V Sachs; P H Pinkerton
Journal:  CMAJ       Date:  1987-04-15       Impact factor: 8.262

2.  Impairment of neutrophil chemotaxis by serum from patients with chronic lymphoproliferative disease.

Authors:  U Jayaswal; S Roper; S Roath
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

3.  Routine flow cytometric diagnosis of lymphoproliferative disorders.

Authors:  I G Barr; B H Toh
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

4.  Spontaneous mouse erythrocyte-rosette formation in chronic lymphocytic leukaemia.

Authors:  E Kuhlein; G Laurent; F Rigal; G Delsol; J Pris; J Ducos
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.